Nova Leap Health - CEO, Chris Dobbin
CEO, Chris Dobbin
Source: YouTube
  • Nova Leap Health (NLH) is seeking to raise up to C$2 million through a non-brokered private placement
  • The company will issue up to 2,777,777 common shares at $0.72 per share
  • Proceeds will be used for acquisition and expansion purposes
  • The offering is scheduled to close on or about June 30, 2021
  • Nova Leap Health is a home health care services company working out of the U.S. and Canada
  • Nova Leap (NLH) is trading flat at $0.79 per share

Nova Leap Health (NLH) is seeking to raise up to C$2 million through a non-brokered private placement.

The company will issue up to 2,777,777 common shares at $0.72 per share and use the proceeds for acquisition and expansion purposes.

The offering is scheduled to close on or about June 30, 2021.

Nova Leap may pay a cash finder’s fee of up to 6 per cent of the proceeds raised from the offering.

Chris Dobbin, President and CEO of Nova Leap, commented,

“We continue to receive quality acquisition opportunities on a regular basis. We recently announced the best quarterly revenue results in the company’s history, and we have plans for significant growth for the remainder of the year. This funding will allow us to act quickly on acquisition opportunities as we continue to scale the business.”

Nova Leap is a home health care services company working out of the U.S. and Canada. The company achieved the #2 ranking on the 2020 Report on Business ranking of Canada’s Top Growing Companies and the #10 ranking in the 2019 TSX Venture 50 in the clean technology & life sciences sector.

Nova Leap (NLH) is trading flat at $0.79 per share as of 12:53 pm ET.

More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.